Amedeo Smart

Free Medical Literature Service

 

Amedeo

Influenza
  Free Subscription

Articles published in
Arch Virol
    April 2024
  1. BEDAIR NM, Sakr MA, Mourad A, Eissa N, et al
    Molecular characterization of the whole genome of H9N2 avian influenza virus isolated from Egyptian poultry farms.
    Arch Virol. 2024;169:99.
    >> Share

  2. KUTKAT O, Gomaa M, Aboulhoda BE, Moatasim Y, et al
    Genetic and virological characteristics of a reassortant avian influenza A H6N1 virus isolated from wild birds at a live-bird market in Egypt.
    Arch Virol. 2024;169:95.
    >> Share

  3. TRAN DH, Do HDK, Tran HT, Pham TNM, et al
    Rapid identification of SARS-CoV-2 strains via isothermal enzymatic recombinase amplification and nanopore sequencing.
    Arch Virol. 2024;169:87.
    >> Share

    March 2024
  4. LI X, Ding G, Li S, Liu C, et al
    Proteomic characteristics of the treatment trajectory of patients with COVID-19.
    Arch Virol. 2024;169:84.
    >> Share

  5. YUAN J, Pan J, Zhang X, Gao R, et al
    TRIM21 reduces H1N1-induced inflammation and apoptosis by regulating the TBK1-IRF3 signaling pathway in A549 cells.
    Arch Virol. 2024;169:74.
    >> Share

    February 2024
  6. KIM HJ, Park JG, Moon KS, Jung SB, et al
    Identification and characterization of a marine bacterium extract from Mameliella sp. M20D2D8 with antiviral effects against influenza A and B viruses.
    Arch Virol. 2024;169:41.
    >> Share

    January 2024
  7. ZHUANG J, Yan Z, Zhou T, Li Y, et al
    The role of receptors in the cross-species spread of coronaviruses infecting humans and pigs.
    Arch Virol. 2024;169:35.
    >> Share

  8. WANG Y, Liu Y, Wang Y, Mai H, et al
    Clinical characteristics of outpatients with influenza-B-associated pneumonia and molecular evolution of influenza B virus in Beijing, China, during the 2021-2022 influenza season.
    Arch Virol. 2024;169:30.
    >> Share

  9. TANIGUCHI K, Noshi T, Omoto S, Sato A, et al
    The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
    Arch Virol. 2024;169:29.
    >> Share

  10. LIU H, Wang J, Li S, Sun Y, et al
    The unfolded protein response pathway as a possible link in the pathogenesis of COVID-19 and sepsis.
    Arch Virol. 2024;169:20.
    >> Share

    November 2023
  11. JAMSHIDINIA N, Saadatpour F, Arefian E, Mohammadipanah F, et al
    Augmented antiviral activity of chlorhexidine gluconate on herpes simplex virus type 1, H1N1 influenza A virus, and adenovirus in combination with salicylic acid.
    Arch Virol. 2023;168:302.
    >> Share

  12. ABDUL-KAREEM HH, Al-Maqtoofi MY, Burghal AA
    Impact of COVID-19 vaccination on saliva immune barriers: IgA, lysozyme, and lactoferrin.
    Arch Virol. 2023;168:293.
    >> Share

  13. WAN L, Li L, Zhang H, Liu C, et al
    The changing pattern of common respiratory viruses among children from 2018 to 2021 in Wuhan, China.
    Arch Virol. 2023;168:291.
    >> Share

    October 2023
  14. MOON SH, Na W, Shin S, Kim H, et al
    Evidence for the circulation of genotype 4 Eurasian avian-like lineage swine H1N1 influenza A viruses on Korean swine farms, obtained using a newly developed one-step multiplex RT-qPCR assay.
    Arch Virol. 2023;168:267.
    >> Share

    September 2023
  15. MESEKO C, Ameji NO, Kumar B, Culhane M, et al
    Rational approach to vaccination against highly pathogenic avian influenza in Nigeria: a scientific perspective and global best practice.
    Arch Virol. 2023;168:263.
    >> Share

  16. DAVE B, Shah KC, Chorawala MR, Shah N, et al
    Molnupiravir: an antiviral drug against COVID-19.
    Arch Virol. 2023;168:252.
    >> Share

  17. DEGIUSEPPE JI, Martelli A, Barrios Mathieur C, Stupka JA, et al
    Genetic diversity of rotavirus A in Argentina during 2019-2022: detection of G6 strains and insights regarding its dissemination.
    Arch Virol. 2023;168:251.
    >> Share

    August 2023
  18. TRIPATHY AS, Wagh P, Akolkar K, Walimbe AM, et al
    Association of inhibitory NKG2A and activating NKG2D natural killer cell receptor genes with resistance to SARS-CoV-2 infection in a western Indian population.
    Arch Virol. 2023;168:237.
    >> Share

  19. PHAM NTK, Khamrin P, Shimizu-Onda Y, Hoque SA, et al
    Genetic diversity and declining norovirus prevalence in infants and children during Japan's COVID-19 pandemic: a three-year molecular surveillance.
    Arch Virol. 2023;168:231.
    >> Share

  20. ZHOU Y, Chen Z
    Mpox: a review of laboratory detection techniques.
    Arch Virol. 2023;168:221.
    >> Share

    July 2023
  21. MA H, Ren S, Meng Q, Su B, et al
    Role of Tim-3 in COVID-19: a potential biomarker and therapeutic target.
    Arch Virol. 2023;168:213.
    >> Share

    June 2023
  22. FAYYAD-KAZAN M, Makki R, Homsi ME, Samadi A, et al
    Circulating microRNA profile in response to remdesivir treatment in coronavirus disease 2019 (COVID-19) patients.
    Arch Virol. 2023;168:194.
    >> Share

  23. LOBAINA Y, Chen R, Suzarte E, Ai P, et al
    Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2.
    Arch Virol. 2023;168:190.
    >> Share

  24. BHANOTHU V, Munne K, Pande S, Singh P, et al
    The dynamics of SARS-CoV-2 infection in unvaccinated and vaccinated populations in Mumbai, India, between 28 December 2020 and 30 August 2021.
    Arch Virol. 2023;168:188.
    >> Share

  25. SENTHILAZHAGAN K, Sakthimani S, Kallanja D, Venkataraman S, et al
    SARS-CoV-2: analysis of the effects of mutations in non-structural proteins.
    Arch Virol. 2023;168:186.
    >> Share

  26. UPADHYAY R, Tiwari KN
    The antiviral potential of Phyllanthus species: a systematic review.
    Arch Virol. 2023;168:177.
    >> Share

  27. VALDES-LOPEZ JF, Urcuqui-Inchima S
    Antiviral response and immunopathogenesis of interleukin 27 in COVID-19.
    Arch Virol. 2023;168:178.
    >> Share

  28. PATTANAIK A, Bhandarkar B S, Lodha L, Marate S, et al
    SARS-CoV-2 and the nervous system: current perspectives.
    Arch Virol. 2023;168:171.
    >> Share

    May 2023
  29. ZHANG Y, Wang J, Xie Y, Cao X, et al
    Epidemiological characteristics of patients from fever clinics during the COVID-19 epidemic in 2022 in Shanghai, China.
    Arch Virol. 2023;168:164.
    >> Share

  30. SUHARSONO H, Mahardika BK, Sudipa PH, Sari TK, et al
    Consensus insertion/deletions and amino acid variations of all coding and noncoding regions of the SARS-CoV-2 Omicron clades, including the XBB and BQ.1 lineages.
    Arch Virol. 2023;168:156.
    >> Share

  31. TATSI EB, Koukou DM, Dellis C, Dourdouna MM, et al
    Epidemiological study of unusual rotavirus strains and molecular characterization of emerging P[14] strains isolated from children with acute gastroenteritis during a 15-year period.
    Arch Virol. 2023;168:149.
    >> Share

    April 2023
  32. MANSOURABADI AH, Aghamajidi A, Dorfaki M, Keshavarz F, et al
    B lymphocytes in COVID-19: a tale of harmony and discordance.
    Arch Virol. 2023;168:148.
    >> Share

  33. DA COSTA MA, de Almeida RPA, Ponde RAA
    Clinical-laboratory profile of children and adolescents with multisystem inflammatory syndrome temporarily associated with COVID-19 in Goias, Brazil.
    Arch Virol. 2023;168:142.
    >> Share

  34. KAWABATA K, Sato Y, Kubo T, Tokumura A, et al
    Phospholipid analysis of two influenza A virus-infected cell lines differing in their viral replication kinetics.
    Arch Virol. 2023;168:132.
    >> Share

    March 2023
  35. MARTINS M, do Nascimento GM, Conforti A, Noll JCG, et al
    A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets.
    Arch Virol. 2023;168:124.
    >> Share

  36. MAO L, Chen Y, Gu J, Zhao Y, et al
    Roles and mechanisms of exosomal microRNAs in viral infections.
    Arch Virol. 2023;168:121.
    >> Share

  37. SHI T, Zhao X, Zhang X, Meng L, et al
    Immediate and long-term changes in the epidemiology, infection spectrum, and clinical characteristics of viral and bacterial respiratory infections in Western China after the COVID-19 outbreak: a modeling study.
    Arch Virol. 2023;168:120.
    >> Share

  38. ZABIHI RIZI F, Ghorbani A, Zahtab P, Darbaghshahi NN, et al
    TYK2 single-nucleotide variants associated with the severity of COVID-19 disease.
    Arch Virol. 2023;168:119.
    >> Share

  39. BORKAKOTI R, Karikalan M, Nehul SK, Jogi HR, et al
    A retrospective study showing a high rate of seropositivity against SARS-CoV-2 in wild felines in India.
    Arch Virol. 2023;168:109.
    >> Share

    February 2023
  40. FALCON-CAMA V, Montero-Gonzalez T, Acosta-Medina EF, Guillen-Nieto G, et al
    Evidence of SARS-CoV-2 infection in postmortem lung, kidney, and liver samples, revealing cellular targets involved in COVID-19 pathogenesis.
    Arch Virol. 2023;168:96.
    >> Share

  41. SALEM S, Mosaad R, Lotfy R, Elbadry M, et al
    Altered expression of DNA methyltransferases and methylation status of the TLR4 and TNF-alpha promoters in COVID-19.
    Arch Virol. 2023;168:95.
    >> Share

  42. NEMOTO M, Reedy SE, Yano T, Suzuki K, et al
    Antigenic comparison of H3N8 equine influenza viruses belonging to Florida sublineage clade 1 between vaccine strains and North American strains isolated in 2021-2022.
    Arch Virol. 2023;168:94.
    >> Share

  43. QUISPE-RICALDE MA, Castelan-Sanchez HG, Meza-Rodriguez PM, Davila-Ramos S, et al
    Evidence of natural selection and dominance of SARS-CoV-2 variant Lambda (C.37) over variants of concern in Cusco, Peru.
    Arch Virol. 2023;168:88.
    >> Share

  44. RAMOS N, Panzera Y, Frabasile S, Tomas G, et al
    A multiplex-NGS approach to identifying respiratory RNA viruses during the COVID-19 pandemic.
    Arch Virol. 2023;168:87.
    >> Share

  45. KAYED AE, Kutkat O, Kandeil A, Moatasim Y, et al
    Comparative pathogenic potential of avian influenza H7N3 viruses isolated from wild birds in Egypt and their sensitivity to commercial antiviral drugs.
    Arch Virol. 2023;168:82.
    >> Share

    January 2023
  46. KHARROUBI G, Cherif I, Ghawar W, Dhaouadi N, et al
    Incidence and risk factors of SARS-CoV-2 infection among workers in a public health laboratory in Tunisia.
    Arch Virol. 2023;168:69.
    >> Share

  47. PANAGIOTIDIS GD, Muller C, Binder M, Weber F, et al
    Influenza A virus strain PR/8/34, but neither HAM/2009 nor WSN/33, is transiently inhibited by the PB2-targeting drug paliperidone.
    Arch Virol. 2023;168:63.
    >> Share

  48. FENG Z, Xu B, Zhong L, Chen J, et al
    A multicentre study on the incidence of respiratory viruses in children with community-acquired pneumonia requiring hospitalization in the setting of the zero-COVID policy in China.
    Arch Virol. 2023;168:64.
    >> Share

  49. MITARAI S, Okuya K, Miyane K, Miyamoto M, et al
    Genetic characterization of bovine respiratory syncytial viruses in Japan between 2017 and 2019.
    Arch Virol. 2023;168:51.
    >> Share

  50. REZAEE D, Bakhtiari S, Jalilian FA, Doosti-Irani A, et al
    Coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus during the COVID-19 pandemic.
    Arch Virol. 2023;168:53.
    >> Share

  51. PUENPA J, Rattanakomol P, Saengdao N, Chansaenroj J, et al
    Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020-2022.
    Arch Virol. 2023;168:26.
    >> Share

  52. VARELA APM, Sant'Anna FH, Dos Santos AV, Prichula J, et al
    Genomic evidence of SARS-CoV-2 reinfection cases in southern Brazil.
    Arch Virol. 2023;168:19.
    >> Share

    December 2022
  53. NIU X, Xu J, Liu M, Tu H, et al
    Isolation and characterization of a SARS-CoV-2 variant with a Q677H mutation in the spike protein.
    Arch Virol. 2022;168:5.
    >> Share

  54. FRAZZINI S, Amadori M, Turin L, Riva F, et al
    SARS CoV-2 infections in animals, two years into the pandemic.
    Arch Virol. 2022;167:2503-2517.
    >> Share

  55. FU Y, Huang Y, Rao J, Zeng F, et al
    Host adaptation of codon usage in SARS-CoV-2 from mammals indicates potential natural selection and viral fitness.
    Arch Virol. 2022;167:2677-2688.
    >> Share

    November 2022
  56. GRACHEVA AV, Korchevaya ER, Ammour YI, Smirnova DI, et al
    Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.
    Arch Virol. 2022;167:2181-2191.
    >> Share

  57. DE OLIVEIRA CM, Romano CM, Sussuchi L, Cota BDCV, et al
    SARS-CoV-2 BA.1 and BA.2 coinfection detected by genomic surveillance in Brazil, January 2022.
    Arch Virol. 2022;167:2271-2273.
    >> Share

    October 2022
  58. DABAJA-YOUNIS H, Fuchs E, Shorbaji N, Appel T, et al
    SARS-CoV-2 and seasonal influenza: similarities and disparities.
    Arch Virol. 2022 Oct 21. pii: 10.1007/s00705-022-05615.
    >> Share

  59. KARIMIAN A, Behjati M, Karimian M
    Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2.
    Arch Virol. 2022;167:1931-1946.
    >> Share

  60. YELEMALI P, Hao L, Liu Q
    Mechanisms of host type I interferon response modulation by the nucleocapsid proteins of alpha- and betacoronaviruses.
    Arch Virol. 2022;167:1925-1930.
    >> Share

    September 2022
  61. LI ZX, Feng S, Zhang H, Zhuang XY, et al
    Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice.
    Arch Virol. 2022 Sep 9. pii: 10.1007/s00705-022-05562.
    >> Share

    August 2022
  62. YANG F, Zhang X, Liu F, Yao H, et al
    Rapid emergence of a PB2 D701N substitution during adaptation of an H9N2 avian influenza virus in mice.
    Arch Virol. 2022 Aug 3. pii: 10.1007/s00705-022-05536.
    >> Share

  63. NAGY A, Stara M, Vodicka R, Cernikova L, et al
    Reverse-zoonotic transmission of SARS-CoV-2 lineage alpha (B.1.1.7) to great apes and exotic felids in a zoo in the Czech Republic.
    Arch Virol. 2022;167:1681-1685.
    >> Share

    July 2022
  64. NGWE TUN MM, Luvai E, Nwe KM, Toume K, et al
    Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro.
    Arch Virol. 2022;167:1547-1557.
    >> Share

  65. BAHLAWAN O, Badra R, Semaan H, Fayad N, et al
    Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon.
    Arch Virol. 2022;167:1509-1519.
    >> Share

    June 2022
  66. DAHER-NASHIF S, Al-Anany R, Ali M, Erradi K, et al
    COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.
    Arch Virol. 2022 Jun 20. pii: 10.1007/s00705-022-05495.
    >> Share

    May 2022
  67. TAKIZAWA N, Momose F
    A novel E198K substitution in the PA gene of influenza A virus with reduced susceptibility to baloxavir acid.
    Arch Virol. 2022 May 5. pii: 10.1007/s00705-022-05456.
    >> Share

  68. PIERI M, Nicolai E, Nuccetelli M, Sarubbi S, et al
    Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
    Arch Virol. 2022;167:1285-1291.
    >> Share

    April 2022
  69. NAGY A, Cernikova L, Stara M
    A new clade 2.3.4.4b H5N1 highly pathogenic avian influenza genotype detected in Europe in 2021.
    Arch Virol. 2022 Apr 26. pii: 10.1007/s00705-022-05442.
    >> Share

  70. JIANG H, Yang T, Yang C, Lu Y, et al
    Molecular epidemiology and clinical characterization of human rhinoviruses circulating in Shanghai, 2012-2020.
    Arch Virol. 2022;167:1111-1123.
    >> Share

  71. MWANGI P, Mogotsi M, Ogunbayo A, Mooko T, et al
    A decontamination strategy for resolving SARS-CoV-2 amplicon contamination in a next-generation sequencing laboratory.
    Arch Virol. 2022;167:1175-1179.
    >> Share

  72. ALEJO-CANCHO I, Gual-de-Torrella A, Gallego M, Urrutikoetxea-Gutierrez M, et al
    Misidentification of the SARS-CoV-2 Mu variant using commercial mutation screening assays.
    Arch Virol. 2022;167:1141-1144.
    >> Share

  73. ATIYA-NASAGI Y, Milrot E, Makdasi E, Schuster O, et al
    Development of an immunofluorescence assay for detection of SARS-CoV-2.
    Arch Virol. 2022;167:1041-1049.
    >> Share

  74. COLSON P, Delerce J, Burel E, Dahan J, et al
    Emergence in southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K substitutions in the spike protein.
    Arch Virol. 2022;167:1185-1190.
    >> Share

  75. WANG Y, Li P, Lavrijsen M, Li Y, et al
    Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
    Arch Virol. 2022;167:1125-1130.
    >> Share

    March 2022
  76. DA SILVA MS, Mosena ACS, Baumbach L, Demoliner M, et al
    Cattle influenza D virus in Brazil is divergent from established lineages.
    Arch Virol. 2022 Mar 17. pii: 10.1007/s00705-022-05416.
    >> Share

  77. BEHESHTIROUY S, Khani E, Khiali S, Entezari-Maleki T, et al
    Investigational antiviral drugs for the treatment of COVID-19 patients.
    Arch Virol. 2022;167:751-805.
    >> Share

  78. LE TB, Kim HK, Ahn MJ, Zanin M, et al
    Diagnostic performance and clinical feasibility of a novel one-step RT-qPCR assay for simultaneous detection of multiple severe acute respiratory syndrome coronaviruses.
    Arch Virol. 2022;167:871-879.
    >> Share

  79. KLOC M, Uosef A, Wosik J, Kubiak JZ, et al
    Virus interactions with the actin cytoskeleton-what we know and do not know about SARS-CoV-2.
    Arch Virol. 2022;167:737-749.
    >> Share

    February 2022
  80. SALEHI-VAZIRI M, Fazlalipour M, Seyed Khorrami SM, Azadmanesh K, et al
    The ins and outs of SARS-CoV-2 variants of concern (VOCs).
    Arch Virol. 2022;167:327-344.
    >> Share

  81. COLSON P, Fantini J, Yahi N, Delerce J, et al
    Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France.
    Arch Virol. 2022;167:583-589.
    >> Share

  82. WANG HX, Zhang L, Liang ZT, Nie JH, et al
    Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal.
    Arch Virol. 2022;167:459-470.
    >> Share

  83. KIM Y, Jang G, Lee D, Kim N, et al
    Trypsin enhances SARS-CoV-2 infection by facilitating viral entry.
    Arch Virol. 2022;167:441-458.
    >> Share

  84. ZHANG L, Guo X, Jiang H, Zhao N, et al
    Decreased incidence of acute hemorrhagic conjunctivitis associated with enhanced public health intervention during the COVID-19 epidemic in China, 2020.
    Arch Virol. 2022;167:577-581.
    >> Share

  85. SHRIVASTAVA S, Mhaske ST, Modak MS, Virkar RG, et al
    Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India.
    Arch Virol. 2022;167:393-403.
    >> Share

  86. SAFARI I, Elahi E
    Evolution of the SARS-CoV-2 genome and emergence of variants of concern.
    Arch Virol. 2022;167:293-305.
    >> Share

    January 2022
  87. FUMAGALLI MJ, Capato CF, de Castro-Jorge LA, de Souza WM, et al
    Stability of SARS-CoV-2 and other airborne viruses under different stress conditions.
    Arch Virol. 2022;167:183-187.
    >> Share

    December 2021
  88. BUITRAGO SP, Garzon-Ospina D
    Genetic diversity of SARS-CoV-2 in South America: demographic history and structuration signals.
    Arch Virol. 2021;166:3357-3371.
    >> Share

  89. TRIPATHY AS, Vishwakarma S, Trimbake D, Gurav YK, et al
    Pro-inflammatory CXCL-10, TNF-alpha, IL-1beta, and IL-6: biomarkers of SARS-CoV-2 infection.
    Arch Virol. 2021;166:3301-3310.
    >> Share

  90. SHI B, Song Q, Luo X, Song J, et al
    Identification of cryptic putative IRESs within the ORF encoding the nonstructural proteins of the human rhinovirus 16 genome.
    Arch Virol. 2021;166:3373-3386.
    >> Share

    November 2021
  91. VIJAYAKUMAR P, Raut AA, Chingtham S, Murugkar HV, et al
    Proteomic analysis of differential expression of lung proteins in response to highly pathogenic avian influenza virus infection in chickens.
    Arch Virol. 2021 Nov 16. pii: 10.1007/s00705-021-05287.
    >> Share

  92. TSUNEKI-TOKUNAGA A, Kondo T, Kanai K, Itagaki A, et al
    Local spread of influenza A (H1N1) viruses without a mutation for the maximum duration of an epidemic season in Japan.
    Arch Virol. 2021 Nov 11. pii: 10.1007/s00705-021-05301.
    >> Share

  93. WANG S, Liu Y, Yu L, Liang T, et al
    A strain of highly pathogenic porcine reproductive and respiratory syndrome virus: genomic characterization, pathogenicity, and construction of an infectious full-length cDNA clone.
    Arch Virol. 2021;166:3127-3141.
    >> Share

  94. RASTEGAR M, Samadizadeh S, Yasaghi M, Moradi A, et al
    Functional variation (Q63R) in the cannabinoid CB2 receptor may affect the severity of COVID-19: a human study and molecular docking.
    Arch Virol. 2021;166:3117-3126.
    >> Share

  95. DU X, Wu G, Zhu Y, Zhang S, et al
    Exploring the epidemiological changes of common respiratory viruses since the COVID-19 pandemic: a hospital study in Hangzhou, China.
    Arch Virol. 2021;166:3085-3092.
    >> Share

  96. RODRIGUEZ-MALDONADO AP, Vazquez-Perez JA, Cedro-Tanda A, Taboada B, et al
    Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico.
    Arch Virol. 2021;166:3173-3177.
    >> Share

    October 2021
  97. JANG Y, Seo SH
    H5 cleavage-site peptide vaccine protects chickens from lethal infection by highly pathogenic H5 avian influenza viruses.
    Arch Virol. 2021 Oct 25. pii: 10.1007/s00705-021-05284.
    >> Share

  98. DOMNICH A, De Pace V, Pennati BM, Caligiuri P, et al
    Evaluation of extraction-free RT-qPCR methods for SARS-CoV-2 diagnostics.
    Arch Virol. 2021;166:2825-2828.
    >> Share

  99. HU J, Stojanovic J, Yasamineh S, Yasamineh P, et al
    The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.
    Arch Virol. 2021;166:2649-2672.
    >> Share

    September 2021
  100. SUN Y, Mao H, Lou X, Wang X, et al
    Molecular epidemiologic characteristics of hemagglutinin from five waves of avian influenza A (H7N9) virus infection, from 2013 to 2017, in Zhejiang Province, China.
    Arch Virol. 2021 Sep 30. pii: 10.1007/s00705-021-05233.
    >> Share

  101. LAVERACK M, Tallmadge RL, Venugopalan R, Cronk B, et al
    Clinical evaluation of a multiplex real-time RT-PCR assay for detection of SARS-CoV-2 in individual and pooled upper respiratory tract samples.
    Arch Virol. 2021;166:2551-2561.
    >> Share

  102. NAGY A, Basiouni S, Parvin R, Hafez HM, et al
    Evolutionary insights into the furin cleavage sites of SARS-CoV-2 variants from humans and animals.
    Arch Virol. 2021;166:2541-2549.
    >> Share

  103. MARCHIO A, Batejat C, Vanhomwegen J, Feher M, et al
    ddPCR increases detection of SARS-CoV-2 RNA in patients with low viral loads.
    Arch Virol. 2021;166:2529-2540.
    >> Share

  104. ABDELWAHAB SF, Mohamed MK, Ali WY, Ali AS, et al
    Role of polymeric materials in preventing COVID-19 infection.
    Arch Virol. 2021;166:2487-2493.
    >> Share

  105. BOONARKART C, Suptawiwat O, Ruangrung K, Maneechotesuwan K, et al
    Microparticles from human the lower airway show inhibitory activity against respiratory syncytial virus.
    Arch Virol. 2021;166:2579-2584.
    >> Share

  106. MA Y, Jiang H, Wan Z, Li S, et al
    Evolutionary dynamics of group A and B respiratory syncytial virus in China, 2009-2018.
    Arch Virol. 2021;166:2407-2418.
    >> Share

    August 2021
  107. PENG J, Liu ZY, Yu XJ, Chen XY, et al
    Antibody response in COVID-19 patients with and without re-positive RT-PCR results during the convalescent phase.
    Arch Virol. 2021;166:2299-2303.
    >> Share

  108. SHABBIR S, Raza MH, Arshad M, Khan MJ, et al
    The interplay between the immune system and SARS-CoV-2 in COVID-19 patients.
    Arch Virol. 2021;166:2109-2117.
    >> Share

  109. HASHEMI SMA, Thijssen M, Hosseini SY, Tabarraei A, et al
    Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection.
    Arch Virol. 2021;166:2089-2108.
    >> Share

  110. ZHANG L, Hou J, Ma FZ, Li J, et al
    The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis.
    Arch Virol. 2021;166:2071-2087.
    >> Share

    July 2021
  111. ZHOU S, Mao N, Zhang Y, Cui A, et al
    Genetic analysis of human parainfluenza virus type 4 associated with severe acute respiratory infection in children in Luohe City, Henan Province, China, during 2017-2018.
    Arch Virol. 2021 Jul 6. pii: 10.1007/s00705-021-05154.
    >> Share

  112. YUAN HW, Wen HL
    Research progress on coronavirus S proteins and their receptors.
    Arch Virol. 2021;166:1811-1817.
    >> Share

  113. MIRZAEI R, Attar A, Papizadeh S, Jeda AS, et al
    The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).
    Arch Virol. 2021;166:1819-1840.
    >> Share

    June 2021
  114. ZENG MS, Yu WD, Wang HX, Xu PP, et al
    Puerarin reduces impairment of intestinal and adipose immune responses to influenza virus infection in mice.
    Arch Virol. 2021 Jun 10. pii: 10.1007/s00705-021-05112.
    >> Share

  115. CHEN K, Kong M, Liu J, Jiao J, et al
    Rapid differential detection of subtype H1 and H3 swine influenza viruses using a TaqMan-MGB-based duplex one-step real-time RT-PCR assay.
    Arch Virol. 2021 Jun 6. pii: 10.1007/s00705-021-05127.
    >> Share

  116. ROKIC F, Trgovec-Greif L, Sucic N, Cemeljic N, et al
    Diverse SARS-CoV-2 variants preceded the initial COVID-19 outbreak in Croatia.
    Arch Virol. 2021;166:1735-1739.
    >> Share

  117. PEDREANEZ A, Mosquera-Sulbaran J, Munoz N
    SARS-CoV-2 infection represents a high risk for the elderly: analysis of pathogenesis.
    Arch Virol. 2021;166:1565-1574.
    >> Share

    May 2021
  118. TANG Y, Yang G, Li Y, Wang M, et al
    Protective effects of SP600125 on mice infected with H1N1 influenza A virus.
    Arch Virol. 2021 May 20. pii: 10.1007/s00705-021-05103.
    >> Share

  119. SOKOLOVA AS, Yarovaya OI, Baranova DV, Galochkina AV, et al
    Quaternary ammonium salts based on (-)-borneol as effective inhibitors of influenza virus.
    Arch Virol. 2021 May 13. pii: 10.1007/s00705-021-05102.
    >> Share

  120. SYLVERKEN AA, El-Duah P, Owusu M, Schneider J, et al
    Transmission of SARS-CoV-2 in northern Ghana: insights from whole-genome sequencing.
    Arch Virol. 2021;166:1385-1393.
    >> Share

    April 2021
  121. GONZALEZ-GARCIA LD, Martinez-Castillo M, Vargas-Pavia TA, Ulloa-Aguilar JM, et al
    Inhibition of AMP-activated protein kinase in respiratory syncytial virus infection activates lipid metabolism.
    Arch Virol. 2021;166:1177-1182.
    >> Share

    March 2021
  122. ZINYAKOV NG, Sosipatorova VY, Andriyasov AV, Ovchinnikova EV, et al
    Genetic analysis of genotype G57 H9N2 avian influenza virus isolate A/chicken/Tajikistan/2379/2018 recovered in Central Asia.
    Arch Virol. 2021 Mar 19. pii: 10.1007/s00705-021-05011.
    >> Share

  123. WOUK J, Rechenchoski DZ, Rodrigues BCD, Ribelato EV, et al
    Viral infections and their relationship to neurological disorders.
    Arch Virol. 2021;166:733-753.
    >> Share

  124. DOWLATSHAHI S, Shabani E, Abdekhodaie MJ
    Serological assays and host antibody detection in coronavirus-related disease diagnosis.
    Arch Virol. 2021;166:715-731.
    >> Share

  125. DABBOUS HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, et al
    Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
    Arch Virol. 2021;166:949-954.
    >> Share

  126. VERMA J, Subbarao N
    A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics.
    Arch Virol. 2021;166:697-714.
    >> Share

  127. SARKAR R, Mitra S, Chandra P, Saha P, et al
    Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations.
    Arch Virol. 2021;166:801-812.
    >> Share

  128. HEMMAT N, Asadzadeh Z, Ahangar NK, Alemohammad H, et al
    The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV.
    Arch Virol. 2021;166:675-696.
    >> Share

    February 2021
  129. YANG F, Xiao Y, Liu F, Yao H, et al
    Isolation and characterization of two novel reassortant H5N6 avian influenza viruses from waterfowl in eastern China.
    Arch Virol. 2021 Feb 17. pii: 10.1007/s00705-021-04995.
    >> Share

  130. LI Y, Hu J, Lei J, Fan W, et al
    Development and application of a novel triplex protein microarray method for rapid detection of antibodies against avian influenza virus, Newcastle disease virus, and avian infectious bronchitis virus.
    Arch Virol. 2021 Feb 12. pii: 10.1007/s00705-021-04962.
    >> Share

  131. TSUNEKI-TOKUNAGA A, Kanai K, Itagaki A, Tsuchie H, et al
    Growth capability of epidemic influenza viruses in Japan since the 2009 H1N1 pandemic.
    Arch Virol. 2021 Feb 12. pii: 10.1007/s00705-021-04976.
    >> Share

    January 2021
  132. ALLKOFER A, Garvey M, Ryan E, Lyons R, et al
    Primary vaccination in foals: a comparison of the serological response to equine influenza and equine herpesvirus vaccines administered concurrently or 2 weeks apart.
    Arch Virol. 2021 Jan 7. pii: 10.1007/s00705-020-04846.
    >> Share

  133. SABBAGHI A, Zargar M, Zolfaghari MR, Motamedi-Sedeh F, et al
    Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model.
    Arch Virol. 2021 Jan 6. pii: 10.1007/s00705-020-04900.
    >> Share

  134. NG KT, Takebe Y, Kamarulzaman A, Tee KK, et al
    Genome sequencing and phylogenetic reconstruction reveal a potential fourth rhinovirus species and its worldwide distribution.
    Arch Virol. 2021;166:225-229.
    >> Share

  135. ARANCIO W
    ceRNA analysis of SARS-CoV-2.
    Arch Virol. 2021;166:271-274.
    >> Share

  136. MOSQUERA-SULBARAN JA, Hernandez-Fonseca H
    Tetracycline and viruses: a possible treatment for COVID-19?
    Arch Virol. 2021;166:1-7.
    >> Share

    December 2020
  137. REHMAN S, Mahmood T, Aziz E, Batool R, et al
    Identification of novel mutations in SARS-COV-2 isolates from Turkey.
    Arch Virol. 2020;165:2937-2944.
    >> Share

    November 2020
  138. YANG X, Liang Y, Bamunuarachchi G, Xu Y, et al
    miR-29a is a negative regulator of influenza virus infection through targeting of the frizzled 5 receptor.
    Arch Virol. 2020 Nov 18. pii: 10.1007/s00705-020-04877.
    >> Share

  139. LIU B, Wang Y, Liu Y, Chen Y, et al
    Molecular evolution and characterization of hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 viruses isolated in Beijing, China, during the 2017-2018 and 2018-2019 influenza seasons.
    Arch Virol. 2020 Nov 3. pii: 10.1007/s00705-020-04869.
    >> Share

  140. DADAR M, Fakhri Y, Bjorklund G, Shahali Y, et al
    The association between the incidence of COVID-19 and the distance from the virus epicenter in Iran.
    Arch Virol. 2020;165:2555-2560.
    >> Share

  141. SHAMIM S, Khan M, Kharaba ZJ, Ijaz M, et al
    Potential strategies for combating COVID-19.
    Arch Virol. 2020;165:2419-2438.
    >> Share

    October 2020
  142. GROHN S, Heinimaki S, Tamminen K, Blazevic V, et al
    Expression of influenza A virus-derived peptides on a rotavirus VP6-based delivery platform.
    Arch Virol. 2020 Oct 16. pii: 10.1007/s00705-020-04847.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016